Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMD11070 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| AMD11070 | DRUG | 200 mg PO BID (by mouth two times per day) for 10 days. |
Inclusion Criteria: * HIV-1 infection, as documented by any licensed ELISA test kit (confirmed by Western Blot), HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, cDNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test. * Both antiretroviral trea...
Top 20 of 28 competitors
AMD11070 is an investigational small molecule being studied for the treatment of HIV infections, specifically in patients carrying X4-tropic virus. It is in Phase 1 clinical development and has not been approved by regulatory authorities.
AMD11070 is being developed by Sanofi, a biopharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 1 clinical trials for HIV infections.
AMD11070 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. The drug is being studied for its potential to treat HIV infections in patients with X4-tropic virus.
AMD11070 has one completed Phase 1 clinical trial, identified as NCT00361101. This study enrolled 10 participants and was conducted in the United States and United Kingdom. The trial focused on HIV-infected patients carrying X4-tropic virus.
AMD11070 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for HIV infections. The drug has not completed the clinical trial process required for regulatory approval.